Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 186 of the 188 references it cites were found in a registry or an index.

The Hippo Signaling Pathway in Drug Resistance in Cancer

Open access
Zeng, Renya, Dong, Jixin · 2021 · Cancers

Abstract

Chemotherapy represents one of the most efficacious strategies to treat cancer patients, bringing advantageous changes at least temporarily even to those patients with incurable malignancies. However, most patients respond poorly after a certain number of cycles of treatment due to the development of drug resistance. Resistance to drugs administrated to cancer patients greatly limits the benefits that patients can achieve and continues to be a severe clinical difficulty. Among the mechanisms which have been uncovered to mediate anti-cancer drug resistance, the Hippo signaling pathway is gaining increasing attention due to the remarkable oncogenic activities of its components (for example, YAP and TAZ) and their druggable properties. This review will highlight current understanding of how the Hippo signaling pathway regulates anti-cancer drug resistance in tumor cells, and currently available pharmacological interventions targeting the Hippo pathway to eradicate malignant cells and potentially treat cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13020318

Cites

186 of 186 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The Hippo signaling pathway in mammalian cells. Only regulators that have been implicated in drug resistance are shown. MST1/2, SAV1, LATS1/2, MOB1, YAP and TAZ compromise the core kinase cascade of the Hippo signaling pathway in mammalian cells. Activated MST1/2-SAV1 complex phosphorylates and activates LATS1/2-MOB1 complex, then the latter phosphorylates YAP/TAZ, leading to their cytoplasmic retention and ubiquitination-mediated degradation in proteasome. The activity of this kinase cascade is regulated by a variety of molecules at multiple levels. KIBRA, hEx and Merlin are upstream regulators that promote the activity of the kinase cascade. The activity of Merlin is regulated by MYPT1-PP1δ phosphatase, which dephosphorylates Merlin and activates it. RASSF family members (for example, RASSF1A and RASSF6) interact with MST1/2 and modulate its kinase activity. In contrast, Ajuba acts as a negative regulator through inhibiting the kinase activity of LATS1/2 and YAP/TAZ phosphorylation.
Figure 1 The Hippo signaling pathway in mammalian cells. Only regulators that have been implicated in drug resistance are shown. MST1/2, SAV1, LATS1/2, MOB1, YAP and TAZ compromise the core kinase cascade of the Hippo signaling pathway in mammalian cells. Activated MST1/2-SAV1 complex phosphorylates and activates LATS1/2-MOB1 complex, then the latter phosphorylates YAP/TAZ, leading to their cytoplasmic retention and ubiquitination-mediated degradation in proteasome. The activity of this kinase cascade is regulated by a variety of molecules at multiple levels. KIBRA, hEx and Merlin are upstream regulators that promote the activity of the kinase cascade. The activity of Merlin is regulated by MYPT1-PP1δ phosphatase, which dephosphorylates Merlin and activates it. RASSF family members (for example, RASSF1A and RASSF6) interact with MST1/2 and modulate its kinase activity. In contrast, Ajuba acts as a negative regulator through inhibiting the kinase activity of LATS1/2 and YAP/TAZ phosphorylation.CC BY · PubMed Central
Figure 2 Targeting the Hippo signaling pathway. Both forskolin and PDE inhibitors elevate the cellular level of cAMP, which facilitates LATS1/2 kinase activity, and consequently leads to YAP phosphorylation, cytoplasmic accumulation and degradation. In addition, dobutamine and statins also induce the phosphorylation of YAP/TAZ. Verteporfin and Super-TDU act as YAP/TAZ inhibitors through blocking the physical interaction between YAP/TAZ and TEADs. The transcription of YAP/TAZ target genes can be impeded by CDK9 inhibitors and BET inhibitors, which block the CDK9 or BRD4-involved transcription process.
Figure 2 Targeting the Hippo signaling pathway. Both forskolin and PDE inhibitors elevate the cellular level of cAMP, which facilitates LATS1/2 kinase activity, and consequently leads to YAP phosphorylation, cytoplasmic accumulation and degradation. In addition, dobutamine and statins also induce the phosphorylation of YAP/TAZ. Verteporfin and Super-TDU act as YAP/TAZ inhibitors through blocking the physical interaction between YAP/TAZ and TEADs. The transcription of YAP/TAZ target genes can be impeded by CDK9 inhibitors and BET inhibitors, which block the CDK9 or BRD4-involved transcription process.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 188 references

Cited by

See all 91

Metadata

Authors
Zeng, R., & Dong, J.
Affiliations
Fred and Pamela Buffett Cancer Center (US)
Corresponding author
Dong, Jixin
Venue
Cancers
Publisher
MDPI AG
Published
2021-01-16
Volume
13
Issue
2
Pages
318
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3121345014
Cited by
89
References
188
Citations by year
2026: 10 · 2025: 24 · 2024: 17 · 2023: 15 · 2022: 13 · 2021: 10
FWCI
1.80
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (R01 GM109066, P30 CA036727)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
Hippo signaling pathway, drug resistance, chemoresistance, YAP, TAZ, cancer, pharmacological targeting, cancer cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Hippo Signaling Pathway in Drug Resistance in Cancer. https://app.cochat.ai/papers/10.3390/cancers13020318
The paper
Zeng, R., & Dong, J. (2021). The Hippo Signaling Pathway in Drug Resistance in Cancer. Cancers. https://doi.org/10.3390/cancers13020318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.